跳至主要内容
临床试验/NL-OMON40554
NL-OMON40554已完成不适用

Advanced PET and MRI techniques for improved therapy response assessment in diffuse large B-cell lymphoma / follicular lymphoma grade 3B - MITRAL; molecular imaging techniques for response assessment in lymphoma

niversitair Medisch Centrum Utrecht0 个研究点目标入组 110 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
110

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99(—)

入选标准

  • - Male or female patients
  • - Age: 18 years and older
  • - Histologically proven diffuse large B-cell lymphoma / Follicular lymphoma grade 3B
  • - Patients scheduled to undergo front-line R-CHOP 21 therapy
  • - Patients must be capable of giving written informed consent and the consent must have been obtained before the study-related procedures

排除标准

  • - General contraindications for MRI (including cardiac pacemakers and claustrophobia). - Previous malignancy. However, subjects who have been free of malignancy for at least 5 years, or have a history of completely resected non-melanoma skin cancer, or successfully treated in situ carcinoma are eligible. - Diffuse large B-cell lymphoma / follicular lymphoma grade 3B central nervous system involvement. - Diffuse large B-cell lymphoma / follicular lymphoma grade 3B stage I disease. - HIV positivity (de novo or active) - Pregnant or lactating women. - Therapy has already started before pretreatment dual-time point 18F-FDG PET and DWI scans could be performed.

研究者

发起方
niversitair Medisch Centrum Utrecht

相似试验